SAN DIEGO (BUSINESS WIRE) MEI Pharma, Inc. (NASDAQ: MEIP), a late-stage pharmaceutical company focused on advancing new therapies for cancer, today announced the grant of inducement stock options for an aggregate of 295,000 shares of the company’s common stock to four new employees. The stock options were granted.
Provided clinical data updates on three programs, including first clinical data on 4D-310 for Fabry disease and 4D-125 and 4D-110 for inherited retinal dystrophies, each demonstrating preliminary. | March 28, 2022
SAN DIEGO, Feb. 10, 2022 Kura Oncology, Inc. , a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced. | February 10, 2022